Rivatroy 2.5 Tablet
Marketer
Troikaa Pharmaceuticals Ltd
Salt Composition
Rivaroxaban (2.5mg)
Overview Rivatroy 2.5 Tablet
A medication called Thrombostop 2.5mg functions as an anticoagulant, preventing and treating blood clots. Its purpose is to mitigate stroke and heart attack risk by inhibiting clot formation in leg, lung, brain, and heart veins. Thrombostop 2.5mg is frequently prescribed for individuals with atrial fibrillation to prevent clotting. It also lowers clot risk post-knee or hip replacement. This medication can be taken with or without food, consistently at the same time daily for optimal results. Long-term use, potentially lifelong, may be necessary. Discontinuing or altering dosage without physician approval significantly increases heart attack, stroke, or thrombosis risk. Lifestyle modifications such as quitting smoking, healthy eating, regular exercise, and weight management further reduce clotting risk. Increased bleeding (e.g., nosebleeds, bruising) is a common side effect; report any symptoms promptly. Contraindicated in patients with severe liver or kidney disease, active bleeding, or concurrent use of other anticoagulants. Breastfeeding is not recommended during treatment. Unlike some anticoagulants, routine PT-INR monitoring is unnecessary.
Primary Ingredients of Rivatroy 2.5 Tablet
No information provided. Please provide the text you wish me to rephrase.
Uses of Rivatroy 2.5 Tablet
Preventing and managing blood clots
Major Benefits of Rivatroy 2.5 Tablet:
Administer this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment duration. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Rivatroy 2.5mg Tablets can be consumed with or without food, although consistent timing is recommended.
Common Side effects of Rivatroy 2.5 Tablet:
- Bleeding
How to use Rivatroy 2.5 Tablet:
Administer this medication precisely as prescribed by your physician, both in terms of dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Rivatroy 2.5mg tablets can be consumed with or without food, though consistent timing is recommended.
How Rivatroy 2.5 Tablet works:
Xarelto 2.5mg tablets represent a new class of oral blood thinners. Their mechanism involves inhibiting factor Xa, a crucial clotting protein, thereby reducing the risk of blood clot development.
SAFETY ADVICE
AlcoholCAUTION
Exercise caution when combining Rivatroy 2.5 Tablet with alcohol. Seek medical advice before doing so.
PregnancyCONSULT YOUR DOCTOR
The use of Rivatroy 2.5 Tablet during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to a developing fetus. A physician will assess the potential advantages against any possible risks prior to prescribing. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
Use of Rivatroy 2.5 Tablet while breastfeeding is likely inadvisable. Available data from humans indicates potential transfer of the medication to breast milk, posing a possible risk to the infant.
DrivingUNSAFE
Driving ability may be impaired by Rivatroy 2.5 Tablet, which can induce dizziness or fainting. The use of Rivatroy 2.5 Tablet may lead to side effects that impact driving capabilities.
KidneyCAUTION
Exercise caution when administering Rivatroy 2.5 mg tablets to individuals with impaired renal function; dosage modification may be necessary. Consult a physician for guidance. Rivatroy 2.5 mg tablets are contraindicated in patients exhibiting severe kidney disease.
LiverUNSAFE
Patients with liver disorders should likely refrain from taking Rivatroy 2.5mg tablets due to potential safety concerns. Medical advice is recommended.
What if you forget to take Rivatroy 2.5 Tablet :
Should you forget a Rivatroy 2.5 Tablet dose, take it promptly. If, however, your next dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Rivatroy 2.5 Tablet
| Label | Value |
|---|---|
| Chemical Category | Morpholine- and thiophene-based derivatives |
| Developing Habits | No. |
| Treatment Category | KINSHIP |
| Behavioral Class | Factor Xa Inhibitors (Oral) |


